Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel in Painful Diabetic Neuropathy or Post-Herpetic Neuralgia
NCT00592904Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2008
- Primary completion
- Nov 2009
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of perampanel in diabetic neuropathy and postherpetic neuralgia (PHN), sponsored by Eisai Co., Ltd. Primary endpoints: Short Form-McGill Pain Questionnaire Sensory and Affective at 48 weeks, Short Form-McGill Pain Questionnaire Visual Analog Scale at 48 weeks and 1 more. Started Jan 2008; status: completed.
02
Drugs
perampanel
03
Conditions
diabetic neuropathypostherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT00592904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00592904.